What is it about?
Colorectal cancer (CRC) is the third most common cancer in the world. However, the clinical use of 5-FU, most effective drug used in the clinic for the treatment of CRC, is limited due to the acquired resistance and systemic toxicity. Here, we develop 5-FU loaded sulfadiazine-poly(lactide-co-glycolide) nanoparticles (SUL-PLGA NPs) to be applied in CRC. In vivo treatment with 5-FU-SUL-PLGA NPs enhanced blood vessel diameters within tumors and significantly reduced tumor growth in vivo, with negligible toxicity. Our findings suggest that the use of 5-FU-SUL-PLGA NPs is a promising strategy to enhance 5-FU efficacy against CRC.
Featured Image
Why is it important?
Our findings suggest that the use of 5-FU-SUL-PLGA NPs is a promising strategy to enhance 5-FU efficacy against CRC.
Perspectives
We hypothesized 5-FU-SUL-PLGA NPs would improve drug release and the antitumor efficacy of 5-FU in vivo. We also investigated the effects of 5-FU-SUL-PLGA NPs on the vasculature of the tumor.
Pedro Guimaraes
Universidade Federal de Minas Gerais
Read the Original
This page is a summary of: Sulfonamide-Functionalized Polymeric Nanoparticles for Enhanced In
Vivo Colorectal Cancer Therapy, Current Drug Delivery, July 2022, Bentham Science Publishers,
DOI: 10.2174/1567201818666210729110127.
You can read the full text:
Contributors
The following have contributed to this page
